Adaptimmune TherapeuticsPharmaceutical Companies

ATIVESITE | Adaptimmune reports updated SURPASS data at ESMO 2021



Adrian Rawcliffe, CEO, and Elliot Norry, CMO – present Adaptimmune’s SURPASS trial data and the Company’s perspective on these results. Clinical responses across 5 solid tumor indications.

Source Adaptimmune Therapeutics
YouTube

 

1111

ativesite

Health First, Well-Being Always!